References
- ConnerCAttaiDAdjuvant endocrine therapy for the surgeon: options, side effects, and their managementAnn Surg Oncol201320103188319323975307
- SmithIEDowsettMAromatase inhibitors in breast cancerNew Engl J Med2003348242431244212802030
- Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ GroupForbesJFCuzickJEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol200891455318083636
- CuzickJSestakIBaumMATAC/LATTE investigatorsEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialLancet Oncol201011121135114121087898
- DaviesCPanHGodwinJAdjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative GroupLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialLancet2013381986980581623219286
- GossPEIngleJNMartinoSA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerN Engl J Med2003349191793180214551341
- JakeszRJonatWGnantMABCSG and the GABGSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialLancet2005366948445546216084253
- BursteinHJPrestrudAASeidenfeldJAmerican Society of Clinical OncologyAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancerJ Clin Oncol201028233784379620625130
- van de VeldeCReaDSeynaeveCAdjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialLancet2011377976232133121247627
- BIG 1-98 Collaborative GroupMouridsenHGiobbie-HurderALetrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med2009361876677619692688
- FabianCJThe what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerInt J Clin Pract200761122051206317892469
- BeresfordMTumurIChakrabartiJBardenJRaoNMakrisAA qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancerClin Oncol (R Coll Radiol)201123320921521134732
- FonteinDBSeynaeveCHadjiPSpecific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysisJ Clin Oncol201331182257226423610112
- FrieseCRPiniTMLiYAdjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancerBreast Cancer Res Treat2013138393193923542957
- BerryJAre all aromatase inhibitors the same? A review of controlled clinical trials in breast cancerClin Ther200527111671168416368441
- Breast International Group (BIG) 1-98 Collaborative GroupThürlimannBKeshaviahAA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
- AmirESerugaBNiraulaSCarlssonLOcanaAToxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysisJ Natl Cancer Inst2011103171299130921743022
- FallowfieldLCellaDCuzickJFrancisSLockerGHowellAQuality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer TrialJ Clin Oncol200422214261427115514369
- ThomasRExamining quality of life issues in relation to endocrine therapy for breast cancerAm J Clin Oncol2003264S40S4412902876
- ThomasRGodwardSMakrisABloomfieldDMoodyAMWilliamsMGiving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozoleClin Oncol (R Coll Radiol)200416748549115490811